

# Preferences of patients and oncologists for the characteristics of the treatment for RCC in Spain and Portugal

**First published:** 30/05/2019

**Last updated:** 30/05/2019

Study

Planned

## Administrative details

### EU PAS number

EUPAS29920

---

### Study ID

29921

---

### DARWIN EU® study

No

---

### Study countries

 Portugal

 Spain

---

### Study description

This is an observational, multicentre, cross-sectional study of RCC (Renal Cell Carcinoma) patients and oncologists from Spain and Portugal. A DCE (Discrete Choice Experiment) will be performed to elicit the preferences of RCC patients and oncologists.

---

### Study status

Planned

## Research institutions and networks

### Institutions

#### Hospital Santa Maria Nai

**First published:** 01/02/2024

**Last updated:** 01/02/2024

Institution

#### Universidad de Valladolid

**First published:** 01/02/2024

**Last updated:** 01/02/2024

Institution

Hospital Santa Maria Nai Ourense (Spain), Hospital Álvaro Cunqueiro Vigo (Spain), Hospital

Universitario Donosti Donostia (Spain), Hospital Universitario Burgos Burgos (Spain), Hospital Universitario de Valladolid Valladolid (Spain), Hospital de Sagunto Sagunto (Spain), Complejo Hospitalario Universitario Insular Materno Infantil Las Palmas (Spain), Instituto Catalán de Oncología (ICO Badalona) Badalona Spain), Instituto Português de Oncologia Francisco Gentil Coimbra (Portugal), Hospital de Santo António dos Capuchos Lisboa (Portugal)

## Contact details

### **Study institution contact**

Salazar Laura [lsalazar@outcomes10.com](mailto:lsalazar@outcomes10.com)

**Study contact**

[lsalazar@outcomes10.com](mailto:lsalazar@outcomes10.com)

### **Primary lead investigator**

Fernández Calvo Ovidio

**Primary lead investigator**

## Study timelines

### **Date when funding contract was signed**

Planned: 01/07/2019

---

### **Study start date**

Planned: 01/07/2019

---

### **Data analysis start date**

Planned: 01/11/2019

---

### **Date of final study report**

Planned: 14/01/2019

## Sources of funding

- Pharmaceutical company and other private sector

## More details on funding

Bristol-Myers Squibb

## Regulatory

### **Was the study required by a regulatory body?**

No

---

### **Is the study required by a Risk Management Plan (RMP)?**

Not applicable

## Methodological aspects

### Study type

**Study type:**

Non-interventional study

---

**Scope of the study:**

Other

**If 'other', further details on the scope of the study**

Patients and oncologists preferences about treatment

**Main study objective:**

The main objective of this project is to determine the preferences of patients and oncologists for the characteristics (attributes) of the treatment for renal cell carcinoma (RCC) in Spain and Portugal. In addition, factors contributing to their preferences will be evaluated.

## Study Design

**Non-interventional study design**

Cross-sectional

## Study drug and medical condition

**Medical condition to be studied**

Renal cell carcinoma

## Population studied

**Age groups**

- Adults (18 to < 46 years)
  - Adults (46 to < 65 years)
  - Adults (65 to < 75 years)
  - Adults (75 to < 85 years)
  - Adults (85 years and over)
- 

### **Estimated number of subjects**

90

## Study design details

### **Outcomes**

To evaluate the differences and similarities among patients and oncologists' preferences regarding RCC treatment attributes. To describe the sociodemographic and clinical characteristics of participants, To identify the characteristics of patients and oncologists which might explain their preferences for RCC treatment attributes. To estimate the willingness to accept a risk or to pay ...

---

### **Data analysis plan**

A descriptive analysis of the socio-demographic and clinical characteristics of the participants will be performed. On the other hand, the results of the DCE (Discrete Choice Experiment) will be analyzed applying a mixed logit model. The influence of individual characteristics on participants' preferences will be explored through multiple linear regression. On the other hand, the correlation between the responses of patients and oncologists will be evaluated. In addition, the willingness to accept a less desirable risk or treatment characteristic in exchange for clinical benefit (MAR) as well as willingness to pay (WTP) will be analyzed.

## Data management

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

## Data sources

### Data sources (types)

Other

---

### Data sources (types), other

Cross-sectional data registry (patient preferences and medical records)

## Use of a Common Data Model (CDM)

### CDM mapping

No

## Data quality specifications

### Check conformance

Unknown

---

### Check completeness

Unknown

---

### Check stability

Unknown

---

**Check logical consistency**

Unknown

**Data characterisation**

**Data characterisation conducted**

No